Peter Shields MD
Research DescriptionPeter Shields, MD, deputy director of The Ohio State University Comprehensive Cancer Center (OSUCCC), is an internationally renowned physician-scientist and expert in cancer prevention. Recently named the president of the American Society of Preventive Oncology, Shields is a leader in researching new biomarkers of cancer risk, molecular epidemiology and carcinogenesis. His primary focus is identifying biomarkers that can be used in the clinic to assess breast and lung cancer risk, particularly those related to diet, smoking and lifestyle. He has published more than 180 studies in scientific journals on topics ranging from toxicology and epidemiology to behavior and health disparities.
As deputy director, Shields oversees the OSUCCC’s research infrastructure and programs, which include more than 280 cancer researchers from 11 of Ohio State’s 14 colleges. He establishes university wide collaborations that translate basic research discoveries into cancer prevention and treatment strategies. Shields has much experience in developing research programs, having received several large multi-investigator grants and contracts. He also has developed education and research partnerships with minority-serving institutions that focus on cancer-related health disparities.
Llanos AA, Brasky TM, Dumitrescu RG, Marian C, Makambi KH, Kallakury BV, Spear SL, Perry DJ, Convit RJ, Platek ME, Adams-Campbell LL, Freudenheim JL, Shields PGPlasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women.Breast Cancer Res Treat 138(2) 571-9 4/1/2013
Han D, Nie J, Bonner MR, Ambrosone C, Marian C, Shields P, Trevisan M, Edge SB, Freudenheim JLClustering of place of birth for women with breast cancer: differences by tumor characteristics.Cancer Causes Control 24(3) 587-94 3/1/2013
Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields P, Trevisan M, Edge SB, Freudenheim JLUse of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis.Cancer Epidemiol Biomarkers Prev 21(1) 239-42 1/1/2012
Shields PLong-term nicotine replacement therapy: cancer risk in context.Cancer Prev Res (Phila) 4(11) 1719-23 11/1/2011
© The Ohio State University